Stoke Therapeutics announced important new data that supports the potential of STK-001 as the first treatment for patients with Dravet syndrome

Stock Therapeutics, the company behind STK-001, presented promising results from a clinical trial for the treatment of the rare and serious epileptic Dravet syndrome. Details of Stoke Therapeutics' achievements can be found on the company's official website: https://investor.stoketherapeutics.com/news-releases/news-release-details/stoke-therapeutics-announces-landmark-new-data-support-potential.S

The development of the drug STK-001 for the treatment of Dravet syndrome is important news in the medical community. Stock Therapeutics continues to work to improve the quality of life of patients suffering from rare and serious diseases.